Back to Journals » Therapeutics and Clinical Risk Management » Volume 10

Cabozantinib for progressive metastatic medullary thyroid cancer: a review

Authors Colombo J, Wein R

Received 10 February 2014

Accepted for publication 19 March 2014

Published 28 May 2014 Volume 2014:10 Pages 395—404

DOI https://doi.org/10.2147/TCRM.S46041

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Joshua R Colombo, Richard O Wein

Department of Otolaryngology, Head and Neck Surgery, Tufts Medical Center, Boston, MA, USA

Abstract: Medullary thyroid cancer is uncommon and patients typically present with advanced disease. Treatment options for patients with progressive, metastatic medullary thyroid cancer had been limited until recently. Tyrosine kinase inhibitors have garnered increasing interest in this subset of patients. The US Food and Drug Administration recently approved cabozantinib, a tyrosine kinase inhibitor, after promising results were shown in a large Phase III clinical trial. This review summarizes the clinical pharmacology, clinical trials, and safety data for cabozantinib and concludes with a discussion of possible future directions for the treatment of medullary thyroid cancer.

Keywords: cabozantinib, tyrosine kinase inhibitor, medullary thyroid cancer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]